Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas

Oral Diseases

Volumn 14, Issue 8, 2008, Pages 741-746

  Demasi, A P D ^a   Magalhaes M H C ^b   Furuse, C ^a   Araujo N S ^b   Junqueira, J L C ^a   Araujo V C ^a  

^a SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Multiple myeloma; Peroxiredoxins; Plasma cell tumor; Plasmablastic lymphoma; Unfolded protein response

Indexed keywords

CELL MARKER; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PEROXIREDOXIN; PEROXIREDOXIN 1; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PEROXIREDOXINS; PLASMA CELLS; PLASMACYTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 54049110009     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01455.x     Document Type: Article

References (47)

1. Acosta-Alvear D, Zhou Y, Blais A et al (2007). XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell 27 : 53 66.
2. Bataille R, Jégo G, Robillard N et al (2006). The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 91 : 1234 1240.
3. Benham AM (2005). Oxidative protein folding: an update. Antioxid Redox Signal 7 : 835 838.
4. Carrasco DR, Sukhdeo K, Protopopova M et al (2007). The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11 : 349 360.
5. Cenci S, Sitia R (2007). Managing and exploiting stress in the antibody factory. FEBS Lett 581 : 3652 3657.
6. Chen WC, McBride WH, Iwamoto KS et al (2002). Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J Neurosci Res 70 : 794 798.
7. Chen MF, Keng PC, Shau H et al (2006). Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64 : 581 591.
8. Colomo L, Loong F, Rives S et al (2004). Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28 : 736 747.
9. Cuozzo JW, Kaiser CA (1999). Competition between glutathione and protein thiols for disulphide-bond formation. Nat Cell Biol 1 : 130 135.
10. Delecluse HJ, Anagnostopoulos I, Dallenbach F et al (1997). Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89 : 1413 1420.
11. Demasi AP, Ceratti D, Furuse C, Cury P, Junqueira JL, Araújo VC (2007). Expression of peroxiredoxin I in plasma cells of oral inflammatory diseases. Eur J Oral Sci 115 : 334 337.
12. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT (2000). Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60 : 749 758.
13. Evens AM, Lecane P, Magda D et al (2005). Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105 : 1265 1273.
14. Goasguen JE, Zandecki M, Mathiot C et al (1999). Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res 23 : 1133 1140.
15. Gross E, Sevier CS, Heldman N et al (2006). Generating disulfides enzymatically: reaction products and electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p. Proc Natl Acad Sci USA 103 : 299 304.
16. Harding HP, Zhang Y, Zeng H et al (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11 : 619 633.
17. Haynes CM, Titus EA, Cooper AA (2004). Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell 15 : 767 776.
18. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7 : 585 598.
19. Hofmann B, Hecht HJ, Flohe L (2002). Peroxiredoxins. Biol Chem 383 : 347 364.
20. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC (2007). Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109 : 2579 2588.
21. Ishii T, Yamada M, Sato H et al (1993). Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J Biol Chem 268 : 18633 18636.
22. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH (2003). Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 4 : 321 329.
23. Jang HH, Lee KO, Chi YH et al (2004). Two enzymes in one: two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 117 : 625 635.
24. Kanemoto S, Kondo S, Ogata M, Murakami T, Urano F, Imaizumi K (2005). XBP1 activates the transcription of its target genes via an ACGT core sequence under ER stress. Biochem Biophys Res Commun 331 : 1146 1153.
25. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH (2005). 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 11 : 571 578.
26. Kimata Y, Ishiwata-Kimata Y, Yamada S, Kohno K (2006). Yeast unfolded protein response pathway regulates expression of genes for anti-oxidative stress and for cell surface proteins. Genes Cells 11 : 59 69.
27. Koong AC, Chauhan V, Romero-Ramirez L (2006). Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther 5 : 756 759.
28. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH (2003). Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 100 : 9946 9951.
29. Lee W, Choi KS, Riddell J et al (2007). Human peroxiredoxin 1 and 2 are not duplicate proteins: the unique presence of CYS83 in Prx1 underscores the structural and functional differences between Prx1 and Prx2. J Biol Chem 282 : 22011 22022.
30. Ludwig H (2005). Advances in biology and treatment of multiple myeloma. Ann Oncol 16 : 106 112.
31. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S (2002). Mechanisms of action of arsenic trioxide. Cancer Res 62 : 3893 3903.
32. Moon JC, Hah YS, Kim WY et al (2005). Oxidative stress-dependent structural and functional switching of a human 2-Cys peroxiredoxin isotype II that enhances HeLa cell resistance to H2O2-induced cell death. J Biol Chem 280 : 28775 28784.
33. Munshi NC, Hideshima T, Carrasco D et al (2004). Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103 : 1799 1806.
34. Nakamura M, Gotoh T, Okuno Y et al (2006). Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leuk Lymphoma 47 : 531 539.
35. Neumann CA, Fang Q (2007). Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7 : 375 380.
36. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH (2006). Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107 : 4907 4916.
37. Reimold AM, Iwakoshi NN, Manis J et al (2001). Plasma cell differentiation requires the transcription factor XBP-1. Nature 412 : 300 307.
38. Rhee SG, Kang SW, Netto LE, Seo MS, Stadtman ER (1999). A family of novel peroxidases, peroxiredoxins. Biofactors 10 : 207 209.
39. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN et al (2004). XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21 : 81 93.
40. Shapiro-Shelef M, Calame K (2004). Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 16 : 226 234.
41. Szegezdi E, Logue SE, Gorman AM, Samali A (2006). Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7 : 880 885.
42. Teruya-Feldstein J (2005). Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep 7 : 357 363.
43. Tu BP, Weissman JS (2004). Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol 164 : 341 346.
44. Vega F, Chang CC, Medeiros LJ et al (2005). Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18 : 806 815.
45. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ (2005). The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65 : 10338 10346.
46. Wood ZA, Schröder E, Robin Harris J, Poole LB (2003). Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28 : 32 40.
47. Zhang B, Su Y, Ai G, Wang Y, Wang T, Wang F (2005). Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res 46 : 305 312.